Shares of BioSyent Inc. (CVE:RX - Get Free Report) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of C$10.98 and traded as low as C$10.98. BioSyent shares last traded at C$11.15, with a volume of 1,201 shares.
BioSyent Price Performance
The stock has a 50 day moving average of C$10.98 and a 200-day moving average of C$10.13. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13. The company has a market cap of C$128.65 million, a PE ratio of 18.58 and a beta of 0.93.
BioSyent (CVE:RX - Get Free Report) last posted its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of C$0.13. The company had revenue of C$8.95 million during the quarter, compared to analyst estimates of C$8.80 million. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. Equities analysts predict that BioSyent Inc. will post 0.6944444 earnings per share for the current year.
Insiders Place Their Bets
In related news, Director Seyed Ahmad Ashrafi sold 2,320 shares of the firm's stock in a transaction on Friday, September 20th. The shares were sold at an average price of C$10.95, for a total transaction of C$25,404.00. Insiders own 33.65% of the company's stock.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Featured Articles
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
